Forte Biosciences, Inc. (FBRX) Fundamental Analysis: Bull vs. Bear Case

FBRX

Forte Biosciences, Inc.

Fundamental data last updated:August 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/13/2026

Business Summary

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

VALUATION

P/E

-46.23

Market Cap ($M USD)

$272.99M

Forward P/E

-3.39

PEG

0.00 PRICE TO SALES

0.00 PRICE TO BOOK

83.30 EV / EBITDA

-2.82

5-Year Average P/E

Free Cash Flow Yield

-21.76%

DCF Value

$0.47

Graham Number

N/A

Price to FCF

-4.60

EV to FCF

-3.62

Earnings Yield

-2.16%

FCF Yield

-21.76%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.43

Next Year EPS Growth Estimate

-$5.80

Next Year Revenue Growth Estimate

$53.42M

Return on Equity (ROE)

-106.16%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00 Piotroski F-Score

1 Altman Z-Score

-1.00

Return on Invested Capital (ROIC)

-176.64%

Current Ratio

2.75 Quick Ratio

2.75 Net Debt to EBITDA

0.76 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-0.33

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

Forte Biosciences, Inc. presents a perplexing valuation scenario. The stock’s market price has historically traded well below its DCF value, suggesting potential mispricing. However, with a Forward P/E of -3.86 and an Earnings Yield of -1.96%, the company is hemorrhaging value, not creating it. Despite a decent Altman Z-score of 3.49 indicating some financial stability, the negative ROIC of -113.91% screams inefficiency. Investors should tread carefully, as the financial health appears fragile.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Forte Biosciences is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, offering potential for transformative growth. However, execution risk remains high given the rapid pace of technological change.

The Bull Case

For the optimistic investor, Forte Biosciences offers a tantalizing opportunity. The company's debt-free balance sheet and a Current Ratio of 3.88 suggest robust liquidity. Despite a dismal Piotroski F-Score of 1, the potential for astronomical sales growth next year could indicate untapped pricing power. The consensus "Buy" rating and a target price of $65.00 reflect institutional confidence in its future prospects.

The Bear Case

The bear case against Forte Biosciences is compelling. A Price/Book ratio of 57.96 indicates severe overvaluation, while the negative FCF Yield of -15.29% highlights cash flow struggles. The stock's proximity to its 52-week high, combined with a volatile 1-Year Beta of 3.005, suggests technical overextension. With no revenue per share and a negative EPS forecast, the structural risks are glaring.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$65.00

Institutional Ownership %

1-Year Beta

3.01 Insider Buying % (6 Mo)

Distance to 52-Week High

82.10%

Distance to 52-Week Low

60.43%

EARNINGS SURPRISE %

-6.90%

50-DAY SMA

$26.53

200-DAY SMA

$21.86

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.